The existence of a cardiomyopathy of obesity is supported by a range of evidence: epidemiologic study findings, which have shown an association between obesity and heart failure; ...

Obesity has an important influence on the development of heart failure, and is recognized as a risk factor for heart failure in the ACC/AHA heart failure guidelines. 1 Obesity cardiomyopathy ...

Obesity and mood disorders increase the risk of peripartum cardiomyopathy (PPCM) during childbirth, reveals research presented at Heart Failure 2015 by Dr David P. Kao, assistant professor at the ...

Obesity cardiomyopathy (OCM) was identified as a distinct pathology associated with sudden cardiac death (SCD) based on records from a national referral center in the U.K. Autopsies showed that ...

Potential Positives. Data published in a peer-reviewed journal support the efficacy of ZyVersa’s Inflammasome ASC Inhibitor IC 100 as a potential treatment for obesity-associated cardiomyopathy ...

We conducted the STEP-HFpEF DM (Semaglutide Treatment Effect in People with Obesity and Heart Failure with Preserved Ejection Fraction and Diabetes Mellitus) trial, a double-blind, randomized ...

We conducted the Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects with Obesity-related Heart Failure with Preserved Ejection Fraction (STEP-HFpEF) trial, a randomized ...

In obesity-associated cardiomyopathy (OAC), heart muscle is structurally and functionally abnormal, impairing the ability to effectively pump blood. Five-year survival rate is less than 50%, with ...

Takotsubo cardiomyopathy is also known as stress cardiomyopathy or broken heart syndrome. It is a temporary heart condition that shares many of the symptoms of a heart attack. Learn more.

ZyVersa Therapeutics (ZVSA) highlights newly published animal model data demonstrating that inflammasome inhibition attenuates obesity-associated cardiomyopathy, which has a 5-year survival rate ...